Device Trial Radar · NCT00824109
Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal Position
Last checked: Nov 19, 2026Latest source record: Dec 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 2008
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Datascope Corp.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this prospective trial is to demonstrate the safety and performance of the Second Generation Anti-Microbial vascular graft in the treatment of aneurysmal and occlusive diseases of the abdominal aorta.
Conditions
- Aneurysmal Disease of the Abdominal Aorta
- Occlusive Disease of the Abdominal Aorta
Interventions
Second Generation Anti-Microbial bifurcated vascular graft (InterGard)Device
treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Graft patency at three yearsTime frame: three years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU La Miletrie, 350 av. Jacques Coeur
86021 Poitiers, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.